Drug Trial Radar · NCT02842827
A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)
Last checked: Nov 19, 2026Latest source record: Jul 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
Oct 6, 2016
Primary completion
Oct 30, 2018
Study completion Oct 30, 2018
Sponsor
- Lead sponsor
- Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)Industry
- Sponsor type
- Industry
- First posted
- Jul 25, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label study of the dose and duration of an orally administered lysine-specific demethylase 1 (LSD1) inhibitor, bomedemstat, in patients with high-risk acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Some participants may also receive all-trans retinoic acid (ATRA; also known as tretinoin and Vesanoid®) in combination with bomedemstat. This study investigates the following: * The safety and tolerability of bomedemstat with and without ATRA * The pharmacodynamic effect of different doses of bomedemstat and treatment durations, as well as bomedemstat administered in combination with ATRA * The pharmacokinetics of bomedemstat with and without ATRA
Conditions
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
Interventions
bomedemstatDrug
oral administration
tretinoinDrug
oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 24 months
- Number of Participants Who Experienced a Serious Adverse Event (SAE)Time frame: Up to approximately 24 months
- Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)Time frame: Up to approximately 18 months
- Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT)Time frame: Up to approximately 28 Days
- Number of Participants Experiencing Any Grade 3 to 5 Adverse Events (AE) as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03Time frame: Up to approximately 24 months
- Number of Participants Who Experienced a Medical Event of Interest (MEOI)Time frame: Up to approximately 24 months
- Maximum Concentration (Cmax) of Bomedemstat Alone or Administered With TretinoinTime frame: Cycle 1 Day 1: predose and 1, 2, 3, and 24 hours postdose; Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose
- Time to Maximum Concentration (Tmax) of Bomedemstat Alone or Administered With TretinoinTime frame: Cycle 1 Day 1: predose and 1, 2, 3, and 24 hours postdose; Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose
- Area Under the Concentration Time Curve From Time 0 to 24 Hours (AUC0-24hr) Postdose of Bomedemstat Alone or Administered With TretinoinTime frame: Cycle 1 Day 1: predose and 1, 2, 3, and 24 hours postdose; Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose
- Elimination Half Life (t1/2) of Bomedemstat Alone or Administered With TretinoinTime frame: Cycle 1 Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose
- Apparent Total Body Clearance (CL/F) of Bomedemstat Alone or Administered With TretinoinTime frame: Cycle 1 Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose
- Volume of Distribution (Vz/F) of Bomedemstat Alone or Administered With TretinoinTime frame: Cycle 1 Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose
- Terminal Elimination Rate Constant (Kel) of Bomedemstat Alone or Administered With TretinoinTime frame: Cycle 1 Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose
- Event-free Survival (EFS) For High-risk Acute Myeloid Leukemia (AML) ParticipantsTime frame: Up to approximately 24 months
- Event-free Survival (EFS) For High-risk Myelodysplastic Syndromes (MDS) ParticipantsTime frame: Up to approximately 24 months
- Overall Survival (OS) For High-risk Acute Myeloid Leukemia (AML) ParticipantsTime frame: Up to approximately 24 months
- Overall Survival (OS) For High-risk Myelodysplastic Syndromes (MDS) ParticipantsTime frame: Up to approximately 24 months
- Objective Response Rate (ORR) For High-risk Acute Myeloid Leukemia (AML) Participants Determined Using the Revised/Modified International Working Group (IWG) Response Criteria (Cheson et al., 2003) and Assessed by the InvestigatorTime frame: Up to approximately 24 months
- Best Overall Response (BOR) For High-risk Acute Myeloid Leukemia (AML) Participants Determined Using the Revised/Modified International Working Group (IWG) Response Criteria (Cheson et al., 2003) and Assessed by the InvestigatorTime frame: Up to approximately 24 months
- Objective Response Rate (ORR) For High-risk Myelodysplastic Syndromes (MDS) Participants Determined Using the Revised/Modified International Working Group (IWG) Response Criteria (Cheson et al., 2006) and Assessed by the InvestigatorTime frame: Up to approximately 24 months
- Best Overall Response (BOR) Assessed by the Revised/Modified International Working Group (IWG) Response Criteria (Cheson et al., 2006): High-risk Myelodysplastic Syndromes (MDS) ParticipantsTime frame: Up to approximately 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.